Advances in anti-epileptic drug testing

Clinica Chimica Acta

Volumn 436, Issue , 2014, Pages 224-236

  Krasowski, Matthew D ^a   McMillin, Gwendolyn A ^b,c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

Anticonvulsants; Drug monitoring; Drug toxicity; Epilepsy; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ESLICARBAZEPINE ACETATE; ETIRACETAM; FELBAMATE; GABAPENTIN; GABAPENTIN ENACARBIL; GABITRI; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PERAMPANEL; PREGABALIN; RETIGABINE; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VIGABATRIN; ZONISAMIDE; ANTICONVULSANTS;

AGRANULOCYTOSIS; APLASTIC ANEMIA; CHRONIC PAIN; CLINICAL SKIN REACTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; EPILEPSY; EPILEPTIC STATE; FIBROMYALGIA; FOCAL EPILEPSY; GAS CHROMATOGRAPHY; GENETIC RISK; GENETIC SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LENNOX GASTAUT SYNDROME; LIQUID CHROMATOGRAPHY; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; PATIENT SELECTION; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SEVERE MYOCLONIC EPILEPSY IN INFANCY; STEVENS JOHNSON SYNDROME; TANDEM MASS SPECTROMETRY; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; HUMANS; METHODS;

ANTICONVULSANTS; DRUG MONITORING; HUMANS;

EID: 84904691348     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.06.002     Document Type: Review

References (215)

1. LaRoche S.M., Helmers S.L. The new antiepileptic drugs: scientific review. JAMA 2004, 291:605-614.
2. Golden A.S., Haut S.R., Moshe S.L. Nonepileptic uses of antiepileptic drugs in children and adolescents. Pediatr Neurol 2006, 34:421-432.
3. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008, 22:27-47.
4. Spina E., Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004, 6:57-75.
5. LaRoche S.M., Helmers S.L. The new antiepileptic drugs: clinical applications. JAMA 2004, 291:615-620.
6. Berg A.T., Millichap J.J. The 2010 revised classification of seizures and epilepsy. Continuum (Minneap Minn) 2013, 19:571-597.
7. Epilepsy CoCaTotILA Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981, 22:489-501.
8. Neels H.M., Sierens A.C., Naelerts K., Scharpé S.L., Hatfield G.M., Lambert W.E. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004, 42:1228-1255.
9. Patsalos P.N., Berry D.J., Bourgeois B.F.D., et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49:1239-1276.
10. Fröscher W., Eichelbaum M., Gugler R., Hildebrand G., Penin H. A prospective randomized trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. J Neurol 1981, 224:193-201.
11. Januzzi G., Cian P., Fattore C., et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. Epilepsia 2000, 41:222-230.
12. Liu H., Delgado M.R. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet 1999, 36:453-470.
13. Patsalos P.N., Berry D.J. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit 2013, 35:4-29.
14. Jones M.D., Ryan M., Miles M.V., et al. Stability of salivary concentrations of the newer antiepileptic drugs in the postal system. Ther Drug Monit 2005, 27:576-579.
15. Ruiz M.E., Conforti P., Fagiolino P., Volonte M.G. The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results. Biopharm Drug Dispos 2010, 31:476-485.
16. Shah N.M., Hawwa A.F., Millership J.S., et al. Adherence to antiepileptic medicines in children: a multiple-methods assessment involving dried blood spot sampling. Epilepsia 2013, 54:1020-1027.
17. Brickel N., Gandhi P., VanLandingham K., Hammond J., DeRossett S. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia 2012, 53:606-612.
18. Chen L., Liu F., Yoshida S., Kaneko S. Is breast-feeding of infants advisable for epileptic mothers taking antiepileptic drugs?. Psychiatry Clin Neurosci 2010, 64:460-468.
19. Warner A., Privitera M., Bates D. Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998, 44:1085-1095.
20. Dasgupta A. Impact of interferences including metabolite crossreactivity on therapeutic drug monitoring results. Ther Drug Monit 2012, 34:496-506.
21. Krasowski M.D., Siam M.G., Iyer M., Ekins S. Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays. Ther Drug Monit 2009, 31:337-344.
22. Krasowski M.D., Siam M.G., Iyer M., Pizon A.F., Giannoutsos S., Ekins S. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Clin Chem 2009, 55:1203-1213.
23. Adaway J.E., Keevil B.G. Therapeutic drug monitoring and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 883-884:33-49.
24. Saint-Marcoux F., Sauvage F.L., Marquet P. Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem 2007, 388:1327-1349.
25. Fortuna A., Alves G., Falcao A. Chiral chromatographic resolution of antiepileptic drugs and their metabolites: a challenge from the optimization to the application. Biomed Chromatogr 2014, 28:27-58.
26. Jacqz-Aigrain E., Guillonneau M., Rey E., et al. Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. Br J Clin Pharmacol 1997, 44:183-185.
27. Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med 2002, 40:986-993.
28. Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 2007, 377:1-13.
29. Za'abi M., Deleu D., Batchelor C. Salivary free concentrations of anti-epileptic drugs: an evaluation in a routine clinical setting. Acta Neurol Belg 2003, 103:19-23.
30. Krasowski M.D. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals (Basel) 2010, 3:1909-1935.
31. Arnaout R., Buck T.P., Roulette P., Sukhatme V.P. Predicting the cost and pace of pharmacogenomic advances: an evidence-based study. Clin Chem 2013, 59:649-657.
32. MacPhee I.A., Holt D.W. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation 2008, 85:163-165.
33. Leckband S.G., Kelsoe J.R., Dunnenberger H.M., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013, 94:324-328.
34. Neuman M.G., Cohen L., Nanau R.M., Hwang P.A. Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl Res 2012, 159:397-406.
35. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013, 103:2-30.
36. Patsalos P.N. New antiepileptic drugs. Ann Clin Biochem 1999, 36:10-19.
37. Nabbout R., Chiron C. Stiripentol: an example of antiepileptic drug development in childhood epilepsies. Eur J Paediatr Neurol 2012, 16(Suppl. 1):S13-S17.
38. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants?. Clin Pharmacokinet 2000, 38:191-204.
39. Asconape J.J. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol 2014, 119:417-432.
40. Tomson T., Landmark C.J., Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 2013, 54:405-414.
41. Giarratano M., Standley K., Benbadis S.R. Clobazam for treatment of epilepsy. Expert Opin Pharmacother 2012, 13:227-233.
42. Wheless J.W., Phelps S.J. Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes. J Child Neurol 2013, 28:219-229.
43. A receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs 2012, 26:229-244.
44. Cramer J.A., Sapin C., Francois C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurol Scand 2013, 128:91-99.
45. Yamamoto Y., Takahashi Y., Imai K., et al. Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy. Ther Drug Monit 2013, 35:305-312.
46. Bolner A., Tagliaro F., Lomeo A. Optimised determination of clobazam in human plasma with extraction and high-performance liquid chromatography analysis. J Chromatogr B Biomed Sci Appl 2001, 750:177-180.
47. de Leon J., Spina E., Diaz F.J. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit 2013, 35:30-47.
48. Knapp J., Boknik P., Gumbinger H.G., et al. Quantitation of clobazam in human plasma using high-performance liquid chromatography. J Chromatogr Sci 1999, 37:145-149.
49. Streete J.M., Berry D.J., Newbery J.E. The analysis of clobazam and its metabolite desmethylclobazam by high-performance liquid chromatography. Ther Drug Monit 1991, 13:339-344.
50. Ambrosio A.F., Silva A.P., Malva J.O., Soares-da-Silva P., Carvalho A.P., Carvalho C.M. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol 2001, 61:1271-1275.
51. Maia J., Vaz-da-Silva M., Almeida L., et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D 2005, 6:201-206.
52. Patsalos P.N., Berry D.J. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother 2012, 13:699-715.
53. Almeida L., Falcao A., Maia J., Mazur D., Gellert M., Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005, 45:1062-1066.
54. Almeida L., Nunes T., Sicard E., et al. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand 2010, 121:257-264.
55. Almeida L., Potgieter J.H., Maia J., Potgieter M.A., Mota F., Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008, 64:267-273.
56. Maia J., Almeida L., Falcao A., et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 2008, 46:119-130.
57. Alves G., Fortuna A., Sousa J., et al. Enantioselective assay for therapeutic drug monitoring of eslicarbazepine acetate: no interference with carbamazepine and its metabolites. Ther Drug Monit 2010, 32:512-516.
58. Loureiro A.I., Fernandes-Lopes C., Wright L.C., Soares-da-Silva P. Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:2611-2618.
59. Porter R.J., Nohria V., Rundfeldt C. Retigabine. Neurotherapeutics 2007, 4:149-154.
60. Yamada M., Welty T.E. Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults. Ann Pharmacother 2012, 46:1358-1367.
61. + channel opener for the treatment of epilepsy. Epilepsia 2012, 53:412-424.
62. Stafstrom C.E., Grippon S., Kirkpatrick P. Ezogabine (retigabine). Nat Rev Drug Discov 2011, 10:729-730.
63. Hermann R., Ferron G.M., Erb K., et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003, 73:61-70.
64. Ferron G.M., Paul J., Fruncillo R., et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002, 42:175-182.
65. Hempel R., Schupke H., McNeilly P.J., et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999, 27:613-622.
66. Borlak J., Gasparic A., Locher M., Schupke H., Hermann R. N-glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism 2006, 55:711-721.
67. Ferron G.M., Patat A., Parks V., Rolan P., Troy S.M. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol 2003, 56:39-45.
68. Knebel N.G., Grieb S., Leisenheimer S., Locher M. Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000, 748:97-111.
69. Pellock J.M., Faught E., Leppik I.E., Shinnar S., Zupanc M.L. Felbamate: consensus of current clinical experience. Epilepsy Res 2006, 71:89-101.
70. Pellock J.M. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf 1999, 21:225-239.
71. Sachdeo R.C., Narang-Sachdeo S.K.H., J.R., et al. Steady-state pharmacokinetics and dose-proportionality of felbamate after oral administration of 1200, 2400, and 3600mg/day of felbamate. Epilepsia 1993, 34:80.
72. Ward D.L., Wagner M.L., Perhach J.L., et al. Felbamate steady-state pharmacokinetics during co-administration of valproate. Epilepsia 1991, 32:8.
73. Sachdeo R.C., Kramer L.D., Rosenberg A., Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992, 32:386-392.
74. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006, 45:351-364.
75. Poquette M.A. Isothermal gas chromatographic method for the rapid determination of felbamate concentration in human serum. Ther Drug Monit 1995, 17:168-173.
76. Annesley T.M., Clayton L.T. Determination of felbamate in human serum by high-performance liquid chromatography. Ther Drug Monit 1994, 16:419-424.
77. Behnke C.E., Reddy M.N. Determination of felbamate concentration in pediatric samples by high-performance liquid chromatography. Ther Drug Monit 1997, 19:301-306.
78. Ettinger A.B., Argoff C.E. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 2007, 4:75-83.
79. McLean M.J. Gabapentin. Epilepsia 1995, 36:S57-S86.
80. Vollmer K.O., von Hodenberg A., Kölle E.U. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 1988, 36:830-839.
81. Berry D.J., Beran R.G., Plunkeft M.J., Clarke L.A., Hung W.T. The absorption of gabapentin following high dose escalation. Seizure 2003, 12:28-36.
82. Gidal B.E., DeCerce J., Bockbrader H.N., et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res 1998, 31:91-99.
83. Wong M.O., Eldon M.A., Keane W.F., et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 1995, 35:622-626.
84. Armijo J.A., Perna M.A., Adin J., Vega-Gil N. Association between patient age and gabapentin serum concentration-to-dose ratio: a preliminary multivariate analysis. Ther Drug Monit 2004, 26:633-637.
85. Lindberger M., Luhr O., Johannessen S.I., Larsson S., Tomson T. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit 2003, 25:457-462.
86. Sivenius J., Kälviäinen R., Ylinen A., Riekkinen P. A double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991, 32:539-542.
87. Juenke J.M., Wienhoff K.A., Anderson B.L., McMillin G.A., Johnson-Davis K.L. Performance characteristics of the ARK diagnostics gabapentin immunoassay. Ther Drug Monit 2011, 33:398-401.
88. Bahrami G., Kiani A. Sensitive high-performance liquid chromatographic quantitation of gabapentin in human serum using liquid-liquid extraction and pre-column derivatization with 9-fluorenylmethyl chloroformate. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 835:123-126.
89. Juenke J.M., Brown P.I., McMillin G.A., Urry F.M. Procedure for the monitoring of gabapentin with 2,4,6-trinitrobenzene sulfonic acid derivatization followed by HPLC with ultraviolet detection. Clin Chem 2003, 49:1198-1201.
90. Ifa D.R., Falci M., Moraes M.E., Bezerra F.A., Moraes M.O., de Nucci G. Gabapentin quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. J Mass Spectrom 2001, 36:188-194.
91. Borrey D.C., Godderis K.O., Engelrelst V.I., Bernard D.R., Langlois M.R. Quantitative determination of vigabatrin and gabapentin in human serum by gas chromatography-mass spectrometry. Clin Chim Acta 2005, 354:147-151.
92. Curia G., Biagini G., Perucca E., Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009, 23:555-568.
93. Chung S., Sperling M.R., Biton V., et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010, 51:958-967.
94. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48:1308-1317.
95. Cawello W., Nickel B., Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol 2010, 50:459-471.
96. Johannessen Landmark C., Patsalos P.N. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010, 10:119-140.
97. Contin M., Albani F., Riva R., Candela C., Mohamed S., Baruzzi A. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 2013, 35:849-852.
98. Greenaway C., Ratnaraj N., Sander J.W., Patsalos P.N. A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy. Ther Drug Monit 2010, 32:448-452.
99. Kestelyn C., Lastelle M., Higuet N., et al. A simple HPLC-UV method for the determination of lacosamide in human plasma. Bioanalysis 2011, 3:2515-2522.
100. Halford J.J., Lapointe M. Clinical perspectives on lacosamide. Epilepsy Curr 2009, 9:1-9.
101. Sabers A., Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol 2009, 22:157-161.
102. Tomson T., Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet 2007, 46:209-219.
103. Incecayir T., Agabeyoglu I., Gucuyener K. Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers. Arzneimittelforschung 2007, 57:517-521.
104. Malone S.A., Eadie M.J., Addison R.S., Wright A.W., Dickinson R.G. Monitoring salivary lamotrigine concentrations. J Clin Neurosci 2006, 13:902-907.
105. Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2006, 2:1009-1018.
106. Hussein Z., Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997, 43:457-464.
107. Reimers A., Helde G., Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005, 46:1414-1417.
108. Sabers A., Buchholt J.M., Uldall P., Hansen E.L. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001, 47:151-154.
109. Fillastre J.P., Taburet A.M., Fialaire A., Etienne I., Bidault R., Singlas E. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drugs Exp Clin Res 1993, 19:25-32.
110. Battino D., Estienne M., Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in pediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 1995, 29:341-369.
111. Italiano D., Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet 2013, 52:627-645.
112. Morris R.G., Black A.B., Harris A.L., Batty A.B., Sallustio B.C. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 1998, 46:547-551.
113. Pennell P.B., Peng L., Newport D.J., et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008, 70:2130-2136.
114. Juenke J.M., Miller K.A., Ford M.A., McMillin G.A., Johnson-Davis K.L. A comparison of two FDA approved lamotrigine immunoassays with ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chim Acta 2011, 412:1879-1882.
115. Westley I.S., Morris R.G. Seradyn quantitative microsphere system lamotrigine immunoassay on a Hitachi 911 analyzer compared with HPLC-UV. Ther Drug Monit 2008, 30:634-637.
116. Angelis-Stoforidis P., Morgan D.J., O'Brien T.J., Vajda F.J. Determination of lamotrigine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999, 727:113-118.
117. Forssblad E., Eriksson A.S., Beck O. Liquid chromatographic determination of plasma lamotrigine in pediatric samples. J Pharm Biomed Anal 1996, 14:755-758.
118. Greiner-Sosanko E., Lower D.R., Virji M.A., Krasowski M.D. Simultaneous determination of lamotrigine, zonisamide, and carbamazepine in human plasma by high-performance liquid chromatography. Biomed Chromatogr 2007, 21:225-228.
119. Lee W., Kim J.H., Kim H.S., Kwon O.H., Lee B.I., Heo K. Determination of lamotrigine in human serum by high-performance liquid chromatography-tandem mass spectrometry. Neurol Sci 2010, 31:717-720.
120. Leppik I.E. The place of levetiracetam in the treatment of epilepsy. Epilepsia 2001, 42:S44-S45.
121. Lynch B.A., Lambeng N., Nocka K., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004, 101:9861-9866.
122. Fay M.A., Sheth R.D., Gidal B.E. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. Clin Ther 2005, 27:594-598.
123. Grim S.A., Ryan M., Miles M.V., et al. Correlation of levetiracetam concentrations between serum and plasma. Ther Drug Monit 2003, 25:61-66.
124. Lins R.L., Otoul C., De Smedt F., Coupez R., Stockis A. Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers. Int J Clin Pharmacol Ther 2007, 45:47-54.
125. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004, 43:707-724.
126. Patsalos P.N., Ghattaura S., Ratnaraj N., Sander J.W. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia 2006, 47:1818-1821.
127. Leppik I.E., Rarick J.O., Walczak T.S., Tran T.A., White J.R., Gumnit R.J. Effective levetiracetam doses and serum concentrations: age effects. Epilepsia 2002, 43:240.
128. Bianchi V., Arfini C., Vidali M. Therapeutic drug monitoring of levetiracetam: comparison of a novel immunoassay with an HPLC method. Ther Drug Monit 2014, (in press).
129. Juenke J.M., McGraw J.P., McMillin G.A., Johnson-Davis K.L. Performance characteristics and patient comparison of the ARK Diagnostics levetiracetam immunoassay with an ultra-high performance liquid chromatography with tandem mass spectrometry detection method. Clin Chim Acta 2012, 413:529-531.
130. Reineks E.Z., Lawson S.E., Lembright K.E., Wang S. Performance characteristics of a new levetiracetam immunoassay and method comparison with a high-performance liquid chromatography method. Ther Drug Monit 2011, 33:124-127.
131. Greiner-Sosanko E., Giannoutsos S., Lower D.R., Virji M.A., Krasowski M.D. Drug monitoring: simultaneous analysis of lamotrigine, oxcarbazepine, 10-hydroxycarbazepine, and zonisamide by HPLC-UV and a rapid GC method using a nitrogen-phosphorus detector for levetiracetam. J Chromatogr Sci 2007, 45:616-622.
132. Vermeij T.A., Edelbroek P.M. High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of levetiracetam (ucb L059) in human serum after solid-phase extraction. J Chromatogr B Biomed Appl 1994, 662:134-139.
133. Pucci V., Bugamelli F., Mandrioli R., Ferranti A., Kenndler E., Raggi M.A. High-performance liquid chromatographic determination of levetiracetam in human plasma: comparison of different sample clean-up procedures. Biomed Chromatogr 2004, 18:37-44.
134. Ratnaraj N., Doheny H.C., Patsalos P.N. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Ther Drug Monit 1996, 18:154-157.
135. Guo T., Oswald L.M., Mendu D.R., Soldin S.J. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry. Clin Chim Acta 2007, 375:115-118.
136. Radtke R.A. Pharmacokinetics of levetiracetam. Epilepsia 2001, 42:24-27.
137. May T.W., Korn-Merker E., Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003, 42:1023-1042.
138. Larkin J.G., McKee P.J., Forrest G., et al. Lack of enzyme induction with oxcarbazepine (600mg daily) in healthy subjects. Br J Clin Pharmacol 1991, 31:65-71.
139. Lloyd P., Flesch G., Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994, (Suppl. 3):10-13.
140. Cardot J.M., Degen P., Flesch G., Menge P., Dieterle W. Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state. Biopharm Drug Dispos 1995, 16:603-614.
141. Miles M.V., Tang P.H., Ryan M.A., et al. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). Ther Drug Monit 2004, 26:300-304.
142. Furlanut M., Franceschi L., Poz D., Silvestri L., Pecorari M. Acute oxcarbazepine, benazepril, and hydrochlorothiazide overdose with alcohol. Ther Drug Monit 2006, 28:267-268.
143. Rouan M.C., Lecaillon J.B., Godbillon J., et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994, 47:161-167.
144. Mazzucchelli I., Onat F.Y., Ozkara C., et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006, 47:504-509.
145. Friis M.L., Kristensen O., Boas J., et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993, 87:224-227.
146. Striano S., Striano P., Di Nocera P., et al. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcabazepine therapy. Epilepsy Res 2006, 69:170-176.
147. von Unruh G.E., Paar W.D. Gas chromatographic assay for oxcarbazepine and its main metabolites in plasma. J Chromatogr 1985, 345:67-76.
148. Juenke J.M., Brown P.I., Urry F.M., McMillin G.A. Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV. J Chromatogr Sci 2006, 44:45-48.
149. Vermeij T.A., Edelbroek P.M. Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 857:40-46.
150. Breton H., Cociglio M., Bressolle F., Peyriere H., Blayac J.P., Hillaire-Buys D. Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 828:80-90.
151. Faulkner M.A. Perampanel: a new agent for adjunctive treatment of partial seizures. Am J Health Syst Pharm 2014, 71:191-198.
152. Plosker G.L. Perampanel: as adjunctive therapy in patients with partial-onset seizures. CNS Drugs 2012, 26:1085-1096.
153. Rogawski M.A. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl 2013, 9-18.
154. Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia 2014, 55(Suppl. 1):13-15.
155. Selak I. Pregabalin (Pfizer). Curr Opin Investig Drugs 2001, 2:828-834.
156. Busch J.A., Strand J.C., Posvar E.L., Bockbrader H.N., Radulovic L.L. Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses. Epilepsia 1998, 39:58.
157. Corrigan B.W., Poole W.F., Posvar E.L., Strand J.C., Alvey C.W., Radulovic L.L. Metabolic disposition of pregabalin in healthy volunteers. Clin Pharmacol Ther 2001, 69:P18.
158. Randinitis E.J., Posvar E.L., Alvey C.W., Sedman A.J., Cook J.A., Bockbrader H.N. Pharmacokinetics of pregabalin in subjects with various degrees of renal functions. J Clin Pharmacol 2003, 43:277-283.
159. Bockbrader H.N., Hunt T., Strand J., Posvar E.L., Sedman A. Pregabalin pharmacokinetics and safety in health volunteers: results from two phase I studies. Neurology 2000, 11:412.
160. Berry D., Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther Drug Monit 2005, 27:451-456.
161. Nirogi R., Kandikere V., Mudigonda K., Komarneni P., Aleti R. Liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry method for the quantification of pregabalin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:3899-3906.
162. Wheless J.W., Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010, 10:1-6.
163. Perucca E., Cloyd J., Critchley D., Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008, 49:1123-1141.
164. Luszczki J.J. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009, 61:197-216.
165. May T.W., Boor R., Rambeck B., Jurgens U., Korn-Merker E., Brandt C. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit 2011, 33:214-221.
166. Contin M., Mohamed S., Candela C., Albani F., Riva R., Baruzzi A. Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:461-465.
167. Chiron C. Stiripentol. Neurotherapeutics 2007, 4:123-125.
168. Fisher J.L. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology 2009, 56:190-197.
169. May T.W., Boor R., Mayer T., et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit 2012, 34:390-397.
170. Levy R.H., Loiseau P., Guyot M., Blehaut H.M., Tor J., Moreland T.A. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 1984, 36:661-669.
171. Tran A., Rey E., Pons G., et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 1997, 62:490-504.
172. Tran A., Vauzelle-Kervroedan F., Rey E., et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol 1996, 50:497-500.
173. Farwell J.R., Anderson G.D., Kerr B.M., Tor J.A., Levy R.H. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia 1993, 34:305-311.
174. Arends R.H., Zhang K., Levy R.H., Baillie T.A., Shen D.D. Stereoselective pharmacokinetics of stiripentol: an explanation for the development of tolerance to anticonvulsant effect. Epilepsy Res 1994, 18:91-96.
175. Gustavson L.E., Mengel H.B. Pharmacokinetics of tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995, 36:605-611.
176. Balslev T., Uldall P., Buchholt J. Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients. Eur J Paediatr Neurol 2000, 4:169-170.
177. Kellinghaus C., Dziewas R., Ludemann P. Tiagabine-related non-convulsive status epilepticus in partial epilepsy: three case reports and a review of the literature. Seizure 2002, 11:243-249.
178. Schapel G., Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure 1996, 5:153-156.
179. Patsalos P.N., Elyas A.A., Ratnaraj N., Iley J. Concentration-dependent displacement of tiagabine by valproic acid. Epilepsia 2002, 43:143.
180. Gustavson L.E., Boellner S.W., Granneman G.R., et al. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997, 48:1032-1037.
181. So E.L., Wolff D., Graves N.M., et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995, 22:221-226.
182. Cato A., Gustavson L.E., Qian J., El-Shourbagy T., Kelly E.A. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine. Epilepsia 1998, 39:43-47.
183. Lau A.H., Gustavson L.E., Sperelakis R., et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997, 38:445-451.
184. Uthman B.M., Rowan A.J., Ahmann P.A., et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998, 55:56-62.
185. Chollet D.F., Castella E., Goumaz L., Anderegg G. Gas chromatography-mass spectrometry assay method for the therapeutic drug monitoring of the antiepileptic drug tiagabine. J Pharm Biomed Anal 1999, 21:641-646.
186. Wang X., Ratnaraj N., Patsalos P.N. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Seizure 2004, 13:574-581.
187. Shibata M., Hashi S., Nakanishi H., Masuda S., Katsura T., Yano I. Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring. Biomed Chromatogr 2012, 26:1519-1528.
188. Williams J., Bialer M., Johannessen S.I., et al. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia 2003, 44:40-45.
189. Easterling D.E., Zakszewski T., Moyer M.D., Margul B.L., Marriott T.B., Nayak R.K. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 1988, 29:662.
190. Miles M.V., Tang P.H., Glauser T.A., et al. Topiramate concentration in saliva: an alternative to serum monitoring. Pediatr Neurol 2003, 29:143-147.
191. Britzi MP E., Soback S., Levy R.H., et al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 2005, 46:378-384.
192. Mimrod D., Specchio L.M., Britzi M., et al. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia 2005, 46:1046-1054.
193. Rosenfeld W.E., Doose D.R., Walker S.A., Baldassarre J.S., Reifer R.A. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol 1999, 20:339-344.
194. Bialer M., Shekh-Ahmad T., Braun T.L., Halvorsen M.B. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Epilepsia 2013, 54:1444-1452.
195. Johannessen S.I., Battino D., Berry D.J., et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003, 25:347-363.
196. Berry D.J., Patsalos P.N. Comparison of topiramate concentrations in plasma and serum by fluorescence polarization immunoassay. Ther Drug Monit 2000, 22:460-464.
197. Snozek C.L., Rollins L.A., Peterson P.W., Langman L.J. Comparison of a new serum topiramate immunoassay to fluorescence polarization immunoassay. Ther Drug Monit 2010, 32:107-111.
198. Riffitts J.M., Gisclon L.G., Stubbs R.J., Palmer M.E. A capillary gas chromatographic assay with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood. J Pharm Biomed Anal 1999, 19:363-371.
199. Mozayani A., Carter J., Nix R. Distribution of topiramate in a medical examiner's case. J Anal Toxicol 1999, 23:556-558.
200. Bahrami G., Mirzaeei S., Kiani A. Sensitive analytical method for topiramate in human serum by HPLC with pre-column fluorescent derivatization and its application in human pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 813:175-180.
201. Christensen J., Hojskov C.S., Poulsen J.H. Liquid chromatography tandem mass spectrometry assay for topiramate analysis in plasma and cerebrospinal fluid: validation and comparison with fluorescence-polarization immunoassay. Ther Drug Monit 2002, 24:658-664.
202. Rey E., Pons G., Olive G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinet 1992, 23:267-278.
203. Schechter P.J. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989, 27:19S-22S.
204. Chang S.Y., Lin W.C. Determination of vigabatrin by capillary electrophoresis with laser-induced fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 794:17-22.
205. Erturk S., Aktas E.S., Atmaca S. Determination of vigabatrin in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 2001, 760:207-212.
206. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998, 20:593-597.
207. Kumagai N., Seki T., Yamada T., Takuma Y., Hirai K. Concentrations of zonisamide in serum, free fraction, mixed saliva and cerebrospinal fluid in epileptic children treated with monotherapy. Jpn J Psychiatry Neurol 1993, 47:291-292.
208. Buchanan R., Bockbrader H.N., Chang T., Sedman A.J. Single- and multiple-dose pharmacokinetics of zonisamide. Epilepsia 1996, 37:172.
209. Perucca E., Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996, 31:29-46.
210. Ijiri Y., Inoue T., Fukuda F., et al. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Epilepsia 2004, 45:924-927.
211. Berent S., Sackellares J.C., Giordani B., Wagner J.G., Donofrio P.D., Abou-Khalil B. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987, 28:61-67.
212. Juenke J., Brown P.I., Urry F.M., McMillin G.A. Drug monitoring and toxicology: a procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. J Anal Toxicol 2006, 30:27-30.
213. Nakamura M., Hirade K., Sugiyama T., Katagiri Y. High-performance liquid chromatographic assay of zonisamide in human plasma using a non-porous silica column. J Chromatogr B Biomed Sci Appl 2001, 755:337-341.
214. Subramanian M., Birnbaum A.K., Remmel R.P. High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry. Ther Drug Monit 2008, 30:347-356.
215. Kim K.B., Seo K.A., Kim S.E., Bae S.K., Kim D.H., Shin J.G. Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 2011, 56:771-777.